On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.
Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."
Data provided by Nasdaq. Minimum 15 minutes delayed.
December 12, 2018
Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita®
PLANO, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received full-body MR-conditional approval for the Company’s Algovita SCS system from its European Notified Body, TÜV SÜD. The approval closely follows the Company’s announcement regarding its receipt of head-only MR-conditional approval for Algovita from the U.S. Food and Drug Administration (FDA). Scott Drees, Chief Executive Officer,
December 06, 2018
Nuvectra Completes 3,000 U.S. Algovita® SCS Implantations
PLANO, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita® Spinal Cord Stimulation (SCS) system has been implanted in over 3,000 patients in the U.S. The Algovita system utilizes patent-protected stretchable lead technology with a robust internal pulse generator to deliver four stimulation modes to patients for non-pharmaceutical relief of pain. Scott Drees, Chief Executive Offi
The Ruth Group
|There are currently no events scheduled.|